OncoMethylome, GSK Agree on Possible Use of DNA Methylation Biomarker

Under the agreement, GlaxoSmithKline may use a DNA methylation-specific biomarker developed by OncoMethylome in its immunotherapeutics program.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories